Legend Biotech (LEGN)
(Delayed Data from NSDQ)
$48.68 USD
+1.20 (2.53%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $48.68 0.00 (0.00%) 6:38 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LEGN 48.68 +1.20(2.53%)
Will LEGN be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for LEGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LEGN
Mortgage Rates Fall to a 12-Month Low
Pre-Markets in Red to Close an Eventful Week, Earnings Mixed
LEGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid
Legend Biotech (LEGN) Surges 12.1%: Is This an Indication of Further Gains?
Should You Buy Legend Biotech (LEGN) Ahead of Earnings?
Other News for LEGN
Legend Biotech (LEGN) Gets a Buy from Jefferies
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients
Legend Biotech (LEGN) Gets a Buy from Scotiabank
Carvykti Poised to Lead CAR-T Space with Strong Efficacy and Market Position: Analyst Outlook
Piper Sandler Sticks to Their Buy Rating for Legend Biotech (LEGN)